Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dihydrohonokiol-B

            Therapeutic Area: Neurology Product Name: TD-010

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 02, 2021

            Details:

            BetterLife has filed patent protection on the newest compound to enter its pipeline, dihydrohonokiol-B (“TD-010”). Specifically, BetterLife has filed for patent protection for the use of TD-010 as a treatment for sedative, hypnotic, or anxiolytic use disorder.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoids

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Solarvest BioEnergy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 04, 2020

            Details:

            Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares to Solarvest, which will enable Solarvest to fund the CBD Research Project.